Collegium Pharmaceutical ( COLL ) Q3 Earnings and Revenues Lag Estimates
Collegium Pharmaceutical (COLL) delivered earnings and revenue surprises of -3.01% and 0.43%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
| Ticker |
Sentiment |
Impact |
|
VVOS
|
Neutral
|
21 %
|
|
COLL
|
Somewhat Bullish
|
40 %
|
